75057-89-5

Upstream product

• 108168-59-8 4-(dimethylamino)benzoyl fluoride 
• 619-84-1 p-N,N-dimethylaminobenzoic acid 
• 4755-50-4 4-(dimethylamino)benzoyl chloride 
• 10287-53-3 ethyl p-dimethyaminolbenzoate 
• 1202-25-1 methyl 4-(N,N-dimethylamino)benzoate 

Downstream Products

• 117867-68-2 4-methoxycarbamoyl-tri-N-methyl-anilinium; iodide 
• 16315-59-6 N,N-dimethylaminophenyl isocyanate 

Relevant academic research and scientific papers

Rhodium(iii)-catalyzed cascade reactions of benzoic acids with dioxazolones: Discovery of 2,5-substituted benzoxazinones as AIE molecules

A rhodium-catalyzed cascade reaction of benzoic acids with 1,4,2-dioxazol-5-ones was studied. The carboxyl group enabled a double C-H amidation followed by further intramolecular cyclization to afford 2,5-substituted benzoxazinones, which exhibited aggregation-induced emission (AIE) properties with a promising excited-state intramolecular proton-transfer (ESIPT) phenomenon.

Synthesis, molecular docking and kinetic properties of β-hydroxy- β-phenylpropionyl-hydroxamic acids as Helicobacter pylori urease inhibitors

Inhibition of urease results in Helicobacter pylori growth arrest in the stomach, promoting urease as promising targets for gastrointestinal ulcer therapy. Twenty hybrid derivatives of flavonoid scaffold and hydroxamic acid, β-hydroxy-β-phenylpropionylhydroxamic acids, were therefore synthesized and evaluated against H. pylori urease. Biological evaluation of these compounds showed improved urease inhibition exhibiting micromolar to mid-nanomolar IC50 values. Most importantly, 3-(3-chlorophenyl)-3- hydroxypropionyl-hydroxamic acid (6g) exhibited high potency with IC 50 of 0.083 ± 0.004 μM and Ki of 0.014 ± 0.003 μM, indicating that 6g is an excellent candidate to develop novel antiulcer agent. A mixture of competitive and uncompetitive mechanism was putatively proposed to understand the inconsistency between the crystallographic and kinetic studies for the first time, which is supported by our molecular docking studies.

Carbonyldiimidazole-mediated lossen rearrangement

[Chemical Equation Presented] Carbonyldiimidazole (CDI) was found to mediate the Lossen rearrangement of various hydroxamic acids to isocyanates. This process is experimentally simple and mild, with imidazole and CO 2 being the sole stoichiometric byproduct. Significant for large-scale application, the method avoids the use of hazardous reagents and thus represents a green alternative to standard processing conditions for the Curtius and Hofmann rearrangements.

Monohydroxamic acids and bridging dihydroxamic acids as chelators to ruthenium(iii) and as nitric oxide donors: Syntheses, speciation studies and nitric oxide releasing investigation

The synthesis and spectroscopic characterisation of novel mononuclear RuIII(edta)(hydroxamato) complexes of general formula [Ru(H 2edta)(monoha)] (where monoha = 3- or 4-NH2, 2-, 3- or 4-Cl and 3-Me-phenylhydroxamato), as well as the first example of a Ru III-N-aryl aromatic hydroxamate, [Ru(H2edta)(N-Me-bha)] ·H2O (N-Me-bha = N-methylbenzohydroxamato) are reported. Three dinuclear RuIII complexes with bridging dihydroxamato ligands of general formula [{Ru(H2edta)}2(μ-diha)] where diha = 2,6-pyridinedihydroxamato and 1,3- or 1,4-benzodihydroxamato, the first of their kind with RuIII, are also described. The speciation of all of these systems (with the exception of the Ru-1,4-benzodihydroxamic acid and Ru-N-methylbenzohydroxamic systems) in aqueous solution was investigated. We previously proposed that nitrosyl abstraction from hydroxamic acids by Ru III involves initial formation of RuIII-hydroxamates. Yet, until now, no data on the rate of nitric oxide (NO) release from hydroxamic acids has been published. We now describe a UV-VIS spectroscopic study, where we monitored the decrease in the ligand-to-metal charge-transfer band of a series of RuIII-monohydroxamates with time, with a view to gaining an insight into the NO-releasing properties of hydroxamic acids. The Royal Society of Chemistry.

Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners

Methods, compounds, and formulations are provided to reduce pigmentation in mammalian skin, comprising hydroxamic acid and its derivatives, and especially benzohydroxamic acid and its derivatives. The compounds preferably inhibit pigment synthesis in melanocytes through inhibition of melanocyte tyrosinase. The methods can be used for lightening skin, and for treating uneven skin complexions, which result from hyperpigmentation-related medical conditions such as melasma, age spots, freckles, ochronosis, and lentigo. The compounds can be used medically or cosmetically, and preferably as topical formulations.

Aminolysis of Benzoyl Fluorides in Water

The reactions of benzoyl fluorides (p-Me2N, p-MeO, m-Cl) with primary amines of pKa = 3.9-11 in aqueous solution follow a first-order dependence on amine concentration and the addition of 0.83 M potassium phosphate, 10percent dianion, does not